SCHEMBL13675953

SCHEMBL13675953

COc1ccc(NC(=O)CCc2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
L3MBTL1 Q9Y468 2/20 0.60
MAPT P10636 1/20 0.60
TRPV1 Q8NER1 2/20 0.58
TSHR P16473 1/20 0.58
ALDH1A1 P00352 5/20 0.57
HTT P42858 1/20 0.57
NR1H4 Q96RI1 2/20 0.56
HPGD P15428 1/20 0.56
HDAC3 O15379 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC1 Q13547 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC2 Q92769 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC8 Q9BY41 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675954 0.88 RAB9A (0.57) KMT2AMEN1L3MBTL1MAPTTRPV1
SCHEMBL13167586 0.86 SMN1; SMN2 (0.72) KMT2AMEN1L3MBTL1MAPTTRPV1
SCHEMBL17069875 0.86 HDAC1 (0.70) MAPTTRPV1HTTNR1H4HDAC3
SCHEMBL13675994 0.85 CA1 (0.64) KMT2AMEN1MAPTTRPV1ALDH1A1
SCHEMBL13675947 0.85 RAB9A (0.75) KMT2AMEN1L3MBTL1MAPTTRPV1
SCHEMBL13676146 0.85 TRPV1 (0.62) KMT2AMEN1MAPTTRPV1ALDH1A1
SCHEMBL13676000 0.85 TRPV1 (0.62) KMT2AMEN1L3MBTL1MAPTTRPV1
SCHEMBL13675963 0.85 TRPV1 (0.62) MAPTTRPV1HTTNR1H4HDAC3
SCHEMBL13676192 0.85 TRPV1 (0.62) MAPTTRPV1HTTNR1H4HDAC3
SCHEMBL13675964 0.85 TRPV1 (0.62) MAPTTRPV1HTTNR1H4HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 KMT2A 3777/4885MEN1 3504/4885L3MBTL1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.